EA202092540A1 - Комбинации для лечения рака - Google Patents

Комбинации для лечения рака

Info

Publication number
EA202092540A1
EA202092540A1 EA202092540A EA202092540A EA202092540A1 EA 202092540 A1 EA202092540 A1 EA 202092540A1 EA 202092540 A EA202092540 A EA 202092540A EA 202092540 A EA202092540 A EA 202092540A EA 202092540 A1 EA202092540 A1 EA 202092540A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combinations
cancer treatment
acceptable salt
pharmaceutically
pentaazaheptacyclo
Prior art date
Application number
EA202092540A
Other languages
English (en)
Inventor
Скотт Бойко
Джастин Сидадо
Лиза Дрю
Тереза Пройа
Марианн Сан Мартин
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA202092540A1 publication Critical patent/EA202092540A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Раскрыты способы лечения рака, включающие введение 17-хлор-5,13,14,22-тетраметил-28-окса-2,9-дитиа-5,6,12,13,22-пентаазагептацикло[27.7.1.14,7.011,15.016,21.020,24.030,35]октатриаконта-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-тридекаен-23-карбоновой кислоты, ее фармацевтически приемлемой соли и акалабрутиниба или его фармацевтически приемлемой соли.
EA202092540A 2018-04-30 2019-04-29 Комбинации для лечения рака EA202092540A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664356P 2018-04-30 2018-04-30
PCT/IB2019/053491 WO2019211721A1 (en) 2018-04-30 2019-04-29 Combinations for treating cancer

Publications (1)

Publication Number Publication Date
EA202092540A1 true EA202092540A1 (ru) 2021-03-17

Family

ID=66794041

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092540A EA202092540A1 (ru) 2018-04-30 2019-04-29 Комбинации для лечения рака

Country Status (14)

Country Link
US (1) US20210030718A1 (ru)
EP (1) EP3787620A1 (ru)
JP (1) JP2021522246A (ru)
KR (1) KR20210005182A (ru)
CN (1) CN112040944A (ru)
AU (1) AU2019263026B2 (ru)
BR (1) BR112020022020A2 (ru)
CA (1) CA3097486A1 (ru)
EA (1) EA202092540A1 (ru)
MA (1) MA52499A (ru)
MX (1) MX2020011453A (ru)
SG (1) SG11202010528XA (ru)
TW (1) TW202014184A (ru)
WO (1) WO2019211721A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005250A (es) * 2019-11-04 2022-06-08 Astrazeneca Ab Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
CN115052880A (zh) * 2019-12-18 2022-09-13 芝诺管理公司 大环化合物
KR20240019283A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항암제의 병용
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192354A (en) 2011-07-19 2022-08-17 Merck Sharp & Dohme 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
AU2015300966A1 (en) * 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
CO2018008759A2 (es) * 2016-04-22 2018-09-20 Astrazeneca Ab Inhibidores de mcl-1 y métodos de uso de los mismos
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法

Also Published As

Publication number Publication date
MX2020011453A (es) 2020-12-07
KR20210005182A (ko) 2021-01-13
SG11202010528XA (en) 2020-11-27
JP2021522246A (ja) 2021-08-30
EP3787620A1 (en) 2021-03-10
CN112040944A (zh) 2020-12-04
US20210030718A1 (en) 2021-02-04
AU2019263026A1 (en) 2020-12-17
CA3097486A1 (en) 2019-11-07
WO2019211721A1 (en) 2019-11-07
BR112020022020A2 (pt) 2021-02-02
MA52499A (fr) 2021-04-14
AU2019263026B2 (en) 2022-06-30
TW202014184A (zh) 2020-04-16

Similar Documents

Publication Publication Date Title
EA202092540A1 (ru) Комбинации для лечения рака
ZA202202097B (en) Amino pyrimidine ssao inhibitors
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201991622A1 (ru) Комплексная терапия для лечения рака
AU2018278311A1 (en) IRE1 small molecule inhibitors
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
EA201990400A1 (ru) Соединения и композиции и их применение
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
MX2021007247A (es) Derivados de rapamicina.
EA202193276A1 (ru) Способы лечения холангиокарциномы
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
EA201892311A1 (ru) Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
ZA202106519B (en) Caspase inhibitors and methods of use thereof
ZA202103975B (en) Methods of treating disease with magl inhibitors
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MX2021000935A (es) Composiciones y metodos terapeuticos para el tratamiento de cancer pancreatico con acido 6,8-bis(bencilsulfanil)octanoico.
EA201650085A1 (ru) Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида
WO2018211324A8 (en) Prodrugs for the treatment of disease